Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
LOKELMA® (sodium zirconium cyclosilicate) is indicated for the treatment of hyperkalaemia in adult patients.
LOKELMA was shown to be generally well tolerated in studies involving 1,760 patients. LOKELMA adverse effects were only mild to moderate, and results showed limited drug-drug interactions.1
Worsening of pre-existing heart failure during treatment was reported as a very common adverse reaction where most cases were resolved with appropriate clinical management without withdrawing Lokelma. The commonly reported adverse reactions were hypokalaemia, oedema related events and constipation.1
In a pooled analysis of three placebo-controlled clinical studies of LOKELMA in non-dialysis patients, some patients with pre-existing heart failure experienced worsening of heart failure, which occurred at a frequency of 13.6% (30/220) on LOKELMA and 5.7% (12/209) on placebo. Most cases resolved with appropriate clinical management without withdrawing LOKELMA1
In clinical trials:
In 2 clinical trials involving 874 patients, the following LOKELMA adverse events were reported:
These events were mild to moderate in nature, with none reported as serious, and generally resolved while the patient continued treatment.1,2
In clinical trials conducted in countries with predominantly Asian populations, LOKELMA resulted in constipation in 8.9% of non-dialysis patients and was resolved with dose adjustment or treatment discontinuation.1
For the safety data and the full list of adverse reactions, please refer to the SmPC.
LOKELMA is not absorbed or metabolised by the body and does not meaningfully bind to other medicinal products, which minimises the potential for significant LOKELMA interactions with other medicinal products. Additionally, other medicinal products have a limited impact on the pharmacologic action of LOKELMA.1
LOKELMA can transiently increase gastric pH by absorbing hydrogen ions. As a result, LOKELMA can affect the solubility and absorption of co-administered drugs that exhibit pH-dependent bioavailability, potentially altering their efficacy or safety profile.1
To avoid interactions, LOKELMA should be administered at least 2 hours before or 2 hours after oral medications with clinically meaningful gastric pH-dependent bioavailability, such as:1
LOKELMA can be co-administered without spacing of dosing times with oral medications that do not exhibit pH-dependent bioavailability.1
LOKELMA is contraindicated in patients who are hypersensitive to the active substance.1
If your patients are being treated with LOKELMA, the following warnings and precautions should be considered:1
Efficacy
View the data behind LOKELMA as a treatment option for hyperkalaemia
Get support
Book a meeting with one of our experts to find out how to implement LOKELMA in your clinical practice
Mode of action
Learn more about the properties of LOKELMA and its mode of action in the management of hyperkalaemia
Dosing and administration
Find out how LOKELMA is administered
ECG, electrocardiogram; GI, gastrointestinal; K+, potassium, RAAS, renin-angiotensin-aldosterone system; SmPC, summary of product characteristics.
GB-74420 | DOP: March 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
